News & Updates
Filter by Specialty:
Meta-analysis favours citalopram in poststroke recovery
Selective serotonin reuptake inhibitors (SSRIs) can prevent and treat depression following stroke, in addition to improving anxiety, dependence, motor function, and cognitive function—benefits that are only reproducible with citalopram but not fluoxetine, according to a meta-analysis said to be the most up to date.
Meta-analysis favours citalopram in poststroke recovery
15 Jul 2022
Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD
Olaparib demonstrates clinical activity across patients with platinum-sensitive relapsed ovarian cancer and known BRCA mutation and homologous recombination deficiency (HRD), as shown in the phase II LIGHT study.
Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD
15 Jul 2022
Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population
Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.
Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population
14 Jul 2022
Upadacitinib works in select ankylosing spondylitis patients
The Janus kinase inhibitor upadacitinib induces significantly higher response than placebo in ankylosing spondylitis patients with inadequate response to biological disease-modifying antirheumatic drugs, without introducing new safety signals, according to data from a phase III trial.